当前位置: X-MOL 学术Cells Tissues Organs › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Control of Hyperglycemia Using Differentiated and Undifferentiated Mesenchymal Stem Cells in Rats with Type 1 Diabetes
Cells Tissues Organs ( IF 2.9 ) Pub Date : 2020-01-01 , DOI: 10.1159/000507790
Ehsan Aali 1 , Zahra Madjd 2 , Neda Tekiyehmaroof 3 , Ali Mohammad Sharifi 4
Affiliation  

Due to their ability in self-renewing and differentiation into a wide variety of tissues, mesenchymal stem cells (MSCs) exhibit outstanding potential for regenerative medicine. This study was aimed at investigating different aspects of MSC therapy in controlling hyperglycemia in streptozotocin-induced diabetes rats. Using an islet cell differentiation protocol, bone marrow (BM) MSCs were differentiated into insulin-producing cells (IPCs). The differentiation process was evaluated by immunocytochemistry, reverse transcriptase PCR, and dithizone staining. Diabetic animals in 4 diabetic individual groups received normal saline, BM-MSCs, coadministration of BM-MSCs with supernatant, and IPCs. Blood glucose and insulin levels were monitored during the experiment. Immunohistochemical analysis of the pancreas was performed at the end of the experiment. Administration of BM-MSCs could not reverse glucose and insulin levels in experimental animals as efficiently as cotransplantation of BM-MSCs with supernatant. The effect of coadministration of BM-MSCs with supernatant and transplantation of IPCs on controlling hyperglycemia is comparable. Immunohistochemical analysis showed that number and size of islets per section were significantly increased in groups receiving IPCs and BM-MSC-supernatant compared to the MSC group of animals. In conclusion, coadministration of BM-MSCs with supernatant could be used as efficiently as IPC transplantation in controlling hyperglycemia in diabetic rats.

中文翻译:

使用分化和未分化间充质干细胞控制 1 型糖尿病大鼠的高血糖

由于间充质干细胞 (MSC) 具有自我更新和分化为多种组织的能力,因此它们在再生医学方面表现出突出的潜力。本研究旨在研究 MSC 治疗在控制链脲佐菌素诱导的糖尿病大鼠高血糖方面的不同方面。使用胰岛细胞分化方案,骨髓 (BM) MSCs 分化为产生胰岛素的细胞 (IPCs)。通过免疫细胞化学、逆转录酶 PCR 和双硫腙染色评估分化过程。4个糖尿病个体组的糖尿病动物接受生理盐水、BM-MSC、BM-MSC与上清液和IPC的共同给药。在实验过程中监测血糖和胰岛素水平。在实验结束时进行胰腺的免疫组织化学分析。BM-MSCs 的给药不能像 BM-MSCs 与上清液的共同移植那样有效地逆转实验动物的葡萄糖和胰岛素水平。BM-MSCs 与上清液的共同给药和 IPCs 移植对控制高血糖的影响是可比的。免疫组织化学分析表明,与 MSC 动物组相比,接受 IPC 和 BM-MSC 上清液的组中每个切片的胰岛数量和大小显着增加。总之,BM-MSCs 与上清液的共同给药可以像 IPC 移植一样有效地控制糖尿病大鼠的高血糖。BM-MSCs 与上清液的共同给药和 IPCs 移植对控制高血糖的影响是可比的。免疫组织化学分析表明,与 MSC 动物组相比,接受 IPC 和 BM-MSC 上清液的组中每个切片的胰岛数量和大小显着增加。总之,BM-MSCs 与上清液的共同给药可以像 IPC 移植一样有效地控制糖尿病大鼠的高血糖。BM-MSCs 与上清液的共同给药和 IPCs 移植对控制高血糖的影响是可比的。免疫组织化学分析表明,与 MSC 动物组相比,接受 IPC 和 BM-MSC 上清液的组中每个切片的胰岛数量和大小显着增加。总之,BM-MSCs 与上清液的共同给药可以像 IPC 移植一样有效地控制糖尿病大鼠的高血糖。
更新日期:2020-01-01
down
wechat
bug